Skip to main content
Clinical Trials/NCT03191071
NCT03191071
Completed
Not Applicable

Procalcitonin and Lung Ultrasonography Point-of-care Testing to Decide on Antibiotic Prescription in Patients With Lower Respiratory Tract Infection at Primary Care Level: Pragmatic Cluster Randomized Trial

Centre Hospitalier Universitaire Vaudois1 site in 1 country469 target enrollmentSeptember 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lower Resp Tract Infection
Sponsor
Centre Hospitalier Universitaire Vaudois
Enrollment
469
Locations
1
Primary Endpoint
Proportion of patients prescribed an antibiotic in each arm
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The study is randomized clustered pragmatic trial whose objective is to decrease unnecessary antibiotic prescription in adult patients with lower respiratory tract infection managed at primary care level in Switzerland, using a simple algorithm based on 2 point of care test results

Detailed Description

The study will have two distinct phases: The first phase will test the feasibility of the intervention (UltraPro) along a pilot study. Following the setup of a lung ultrasound training curriculum for general practitioners, the practicality of the whole UltraPro algorithm will be evaluated at primary care level. The second phase will be a pragmatic randomized three-arm intervention study using an algorithm based on the results of procalcitonin and lung ultrasound to manage patients with lower respiratory tract infections at primary care level. The procalcitonin-ultrasound algorithm will be compared to procalcitonin-guided management alone and usual care.

Registry
clinicaltrials.gov
Start Date
September 1, 2018
End Date
April 30, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr Boillat-Blanco Noemie

Principal Investigator

Centre Hospitalier Universitaire Vaudois

Eligibility Criteria

Inclusion Criteria

  • Informed Consent as documented by signature (Informed Consent Form)
  • Patients aged 18 years or more
  • No antibiotics prescribed for the current episode
  • Acute cough of up to 21 days duration and at least one of the following symptom or sign:
  • History of fever for more than 4 days
  • tachypnoea (≥ 22 cycles per minutes)
  • abnormal focal finding during auscultation

Exclusion Criteria

  • Previous prescription of antibiotics for the current episode
  • Working diagnosis of acute sinusitis or a non-infective disorder
  • Cystic fibrosis
  • Previous episode of chronic obstructive pulmonary disease exacerbation treated with antibiotics during the last 6 months
  • Known pregnancy
  • Severe immunodeficiency (untreated HIV infection with CD4 count \< 200 cells/mm3, solid organ transplant receiver, neutropenia, treatment with corticosteroids with dose equivalent to 20 mg prednisone/day for \> 28
  • Admission of the patient
  • GP not available for performing study
  • Patient unable to provide informed consent

Outcomes

Primary Outcomes

Proportion of patients prescribed an antibiotic in each arm

Time Frame: Assessed at day 28 after baseline

For each arm, we will assess the proportion of patient's prescribed an antibiotic following the consultation with the general practitioner. This will be done by recording the prescription decision of the general practitioner.

Secondary Outcomes

  • Serious adverse outcome(During the first 28 days following baseline)
  • Duration of algorithm completion(Assessed at baseline (Day 0))
  • Aetiology of LRTIs in primary care(Assessed within the first year after data collection is complete)
  • Duration of the episode(Assessed at day 28 after baseline)
  • Transcription patterns(Assessed within the first year after data collection is complete)
  • Host biomarkers(Assessed within the first year after data collection is complete)
  • Clinical failure(Day 7 after baseline)
  • Cost / effectiveness ratio(Assessed one month after data collection is complete)
  • Number of medical visits(Day 7 and Day 28 after baseline)
  • Satisfaction of providers(Assessed at baseline)
  • Satisfaction of patients(Assessed at day 7)

Study Sites (1)

Loading locations...

Similar Trials